PAH, Pulmonary HTN, Clinical Trials
Our Pulmonary Hypertension Center
October 17, 2008, 11:55
Lexington Pulmonary and Critical Care has one of the most active Pulmonary Arterial Hypertension diagnosis and treatment centers in South Carolina. We see patients referred from cardiologists, pulmonologists, internists, rheumatologists, and other specialists for pulmonary hypertension and complete a full evaluation to determine if the disease exists, why it exists, and what the best treatment options are or the individual patient.
We also offer participation in several clinical trials to assure that our patients can receive the latest in State-of-the-art care right here in the Columbia/Lexington area that used to be available only at major medical centers.
As of today (October 17, 2008) we are actively following 199 patients with known or suspected pulmonary hypertension.
We have the following number of patients on the various approved therapy for pulmonary hypertension:
Tracleer (bosentan) 45
Letairis (ambrisentan) 16
Revatio (sildenafil) 39
Ventavis (iloprost) 9
Remodulin (treprostinil) 1
We are currently recruiting patients for the following clinical trials related to treatment of pulmonary arterial hypertension:
COMPASS-2 study - This is a drug study sponsored by Actelion Pharmaceuticals testing the combination of sildenafil and bosentan for treatment of Pulmonary Arterial Hypertension.
Athena-1 study - This is a drug study sponsored by Gilead pharmaceuticals to evaluate the safety and effectiveness of the combination of sildenafil and ambrisentan for treatment of Pulmonary Arterial Hypertension.
Aries-3 study - This is a drug study sponsored by Gilead pharmaceuticals to evaluate the safety and effectiveness of ambrisentan for treatment of Pulmonary Arterial Hypertension.
ABS-LT study - This is the long-term extension study for AIRES-3.
REVEAL registry - This is a registry study sponsored by Actelion Pharmaceuticals to record data on patients treated for pulmonary hypertension.
For referrals call our office at 803-520-5100 or send email to delton@lexpcc.net.
We also offer participation in several clinical trials to assure that our patients can receive the latest in State-of-the-art care right here in the Columbia/Lexington area that used to be available only at major medical centers.
As of today (October 17, 2008) we are actively following 199 patients with known or suspected pulmonary hypertension.
We have the following number of patients on the various approved therapy for pulmonary hypertension:
Tracleer (bosentan) 45
Letairis (ambrisentan) 16
Revatio (sildenafil) 39
Ventavis (iloprost) 9
Remodulin (treprostinil) 1
We are currently recruiting patients for the following clinical trials related to treatment of pulmonary arterial hypertension:
COMPASS-2 study - This is a drug study sponsored by Actelion Pharmaceuticals testing the combination of sildenafil and bosentan for treatment of Pulmonary Arterial Hypertension.
Athena-1 study - This is a drug study sponsored by Gilead pharmaceuticals to evaluate the safety and effectiveness of the combination of sildenafil and ambrisentan for treatment of Pulmonary Arterial Hypertension.
Aries-3 study - This is a drug study sponsored by Gilead pharmaceuticals to evaluate the safety and effectiveness of ambrisentan for treatment of Pulmonary Arterial Hypertension.
ABS-LT study - This is the long-term extension study for AIRES-3.
REVEAL registry - This is a registry study sponsored by Actelion Pharmaceuticals to record data on patients treated for pulmonary hypertension.
For referrals call our office at 803-520-5100 or send email to delton@lexpcc.net.